JP2017523141A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523141A5
JP2017523141A5 JP2016572482A JP2016572482A JP2017523141A5 JP 2017523141 A5 JP2017523141 A5 JP 2017523141A5 JP 2016572482 A JP2016572482 A JP 2016572482A JP 2016572482 A JP2016572482 A JP 2016572482A JP 2017523141 A5 JP2017523141 A5 JP 2017523141A5
Authority
JP
Japan
Prior art keywords
formula
compound
symptoms
optionally substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572482A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663863B2 (ja
JP2017523141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/035659 external-priority patent/WO2015192078A1/en
Publication of JP2017523141A publication Critical patent/JP2017523141A/ja
Publication of JP2017523141A5 publication Critical patent/JP2017523141A5/ja
Application granted granted Critical
Publication of JP6663863B2 publication Critical patent/JP6663863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572482A 2014-06-12 2015-06-12 がん治療のための組成物及び方法 Active JP6663863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011413P 2014-06-12 2014-06-12
US62/011,413 2014-06-12
PCT/US2015/035659 WO2015192078A1 (en) 2014-06-12 2015-06-12 Compositions and methods for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020023904A Division JP7015856B2 (ja) 2014-06-12 2020-02-17 がん治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2017523141A JP2017523141A (ja) 2017-08-17
JP2017523141A5 true JP2017523141A5 (https=) 2018-07-26
JP6663863B2 JP6663863B2 (ja) 2020-03-13

Family

ID=54834452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016572482A Active JP6663863B2 (ja) 2014-06-12 2015-06-12 がん治療のための組成物及び方法
JP2020023904A Active JP7015856B2 (ja) 2014-06-12 2020-02-17 がん治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020023904A Active JP7015856B2 (ja) 2014-06-12 2020-02-17 がん治療のための組成物及び方法

Country Status (10)

Country Link
US (4) US10029997B2 (https=)
EP (2) EP4306173A3 (https=)
JP (2) JP6663863B2 (https=)
KR (1) KR102567244B1 (https=)
CN (1) CN106794175B (https=)
AU (3) AU2015274334B2 (https=)
CA (1) CA2950774C (https=)
ES (1) ES2960601T3 (https=)
MX (1) MX388409B (https=)
WO (1) WO2015192078A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794175B (zh) 2014-06-12 2020-06-09 西达-赛奈医疗中心 用于治疗癌症的组合物
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
CN115569196B (zh) * 2020-02-26 2024-06-18 上海科技大学 多酚类物质在抗冠状病毒中的应用
CN111658766A (zh) * 2020-07-06 2020-09-15 陈长宏 GSK3β及其激动剂在上皮源性恶性肿瘤治疗与康复中的应用
EP4558133A1 (en) * 2022-07-21 2025-05-28 Agency for Science, Technology and Research Method of inhibiting epithelial-mesenchymal transition and cancer metastasis
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
WO2025240627A1 (en) * 2024-05-14 2025-11-20 Cedars-Sinai Medical Center Methods and compositions for treating pancreatic cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711492A (en) * 1970-12-08 1973-01-16 Basf Ag Thiadiazolidinediones
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US6045925A (en) 1997-08-05 2000-04-04 Kansas State University Research Foundation Encapsulated nanometer magnetic particles
EP1165500A1 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
CN1764655A (zh) * 2001-05-11 2006-04-26 法马西亚公司 芳族砜异羟肟酸酯及其作为蛋白酶抑制剂的用途
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6676729B2 (en) 2002-01-02 2004-01-13 International Business Machines Corporation Metal salt reduction to form alloy nanoparticles
EP1339075A1 (en) 2002-02-25 2003-08-27 Motorola, Inc. Magnetic nanomaterials and synthesis method
US6878445B2 (en) 2002-03-08 2005-04-12 Fuji Photo Film Co., Ltd. Nanoparticle coated material and production method of same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US7812016B2 (en) * 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
TW593158B (en) 2003-07-31 2004-06-21 Ind Tech Res Inst Magnetic nanoparticle
US7396589B2 (en) 2003-07-31 2008-07-08 Industrial Technology Research Institute Core-shell magnetic nanoparticles comprising an inner-transition element
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
GB0402496D0 (en) * 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US7700193B2 (en) 2005-04-08 2010-04-20 Industrial Technology Research Institute Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof
US20070264199A1 (en) 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US9180118B2 (en) * 2006-07-18 2015-11-10 University Of Rochester Thiadiazolidinone derivatives
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン,インコーポレーテッド 抗菌剤
CA2708149A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2012012320A1 (en) * 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
ES2632428T3 (es) * 2012-02-24 2017-09-13 Asd Therapeutics Partners Llc Nuevas tiadiazolidinadionas como inhibidores de GSK-3
JP5722264B2 (ja) 2012-03-23 2015-05-20 株式会社日立ハイテクノロジーズ データ処理装置、データ容量増加抑制方法
JP6329958B2 (ja) 2012-11-07 2018-05-23 カルス セラピューティクス リミテッド 新規ヒストンデアセチラーゼインヒビターおよび治療におけるその使用
CN103848795B (zh) 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN106794175B (zh) 2014-06-12 2020-06-09 西达-赛奈医疗中心 用于治疗癌症的组合物

Similar Documents

Publication Publication Date Title
JP2017523141A5 (https=)
JP2015532295A5 (https=)
JP2015522650A5 (https=)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2019510832A5 (https=)
JP2019524883A5 (https=)
JP2016513137A5 (https=)
JP2008535902A5 (https=)
JP2018504379A5 (https=)
JP2016515561A5 (https=)
JP2009536620A5 (https=)
JP2008535903A5 (https=)
JP2014193925A5 (https=)
JP2010539095A5 (https=)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2017506666A5 (https=)
JP2015500884A5 (https=)
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
EA201101507A1 (ru) Способы лечения солидных опухолей
RU2017104856A (ru) Функционализированные и замещенные индолы в качестве противораковых средств
JP2010511721A5 (https=)
JP2019529444A5 (https=)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2013520443A5 (https=)
JP2010524947A5 (https=)